Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Current therapies for adults with recurrent or refractory mixed gliomas provide
very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy
suggest that it may prove beneficial in the treatment of adults with recurrent or refractory
mixed gliomas.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on adults with recurrent or refractory mixed gliomas.